Immunotherapy combo shows promise in advanced lung cancer trial

NCT ID NCT03607539

Completed Disease control Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 study tested whether adding the immunotherapy drug sintilimab to standard chemotherapy helps people with advanced non-squamous non-small cell lung cancer. 397 participants received either sintilimab plus chemo or a placebo plus chemo. The main goal was to see if the combination delayed cancer growth. Results showed that sintilimab improved progression-free survival, meaning the cancer took longer to worsen.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sintilimab (an immunotherapy drug) combined with pemetrexed and platinum chemotherapy
What this could lead to: If successful, this combination could become a standard first-line treatment for advanced non-squamous lung cancer, helping patients live longer without their cancer growing.
What could go wrong: This is a completed phase 3 trial, but results may not apply to all patients. Immunotherapy can cause immune-related side effects, and not everyone responds to the treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG NEOPLASMS

Contacts and locations

Locations

Sun Yat-Sen University Cancer Center

Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.